AR080754A1 - Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 - Google Patents

Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Info

Publication number
AR080754A1
AR080754A1 ARP110100694A ARP110100694A AR080754A1 AR 080754 A1 AR080754 A1 AR 080754A1 AR P110100694 A ARP110100694 A AR P110100694A AR P110100694 A ARP110100694 A AR P110100694A AR 080754 A1 AR080754 A1 AR 080754A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
group
hydrogen
substituted
Prior art date
Application number
ARP110100694A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR080754A1 publication Critical patent/AR080754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a nuevos derivados de imidazo[1,2-a]pirazina que son inhibidores de la enzima fosfodiesterasa 10 (PDE10) y que resultan utiles para el tratamiento o la prevencion de trastornos neurologicos, psiquiátricos y metabolicos en los cuales participa la enzima PDE10. También se dirige a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos o composiciones farmacéuticas para la prevencion o el tratamiento de trastornos y enfermedades neurologicas, psiquiátricas y metabolicas. Reivindicacion 1: Un compuesto de formula (1) o una forma estereoisomérica de dicho compuesto, en donde R1 se selecciona del grupo que consiste en un radical de formula (a-1), (a-2) y (a-3); en donde cada R6, R7, R8 se selecciona independientemente del grupo que consiste en fluoro; alquilo C1-4, alquiloxi C1-4 y alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; R9 es hidrogeno o alquilo C1-4; cada m1, m2 y m3 se selecciona independientemente de 0, 1, 2, 3 y 4; p2 se selecciona de 1, 2, 3 y 4; cada p1 Y p3 se selecciona independientemente de 1 y 2; o R1 se selecciona del grupo que consiste en piridinilo no sustituido; piridinilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo y alquiloxi C1-4; y tetrahidropiranilo no sustituido; R2 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, trifluorometilo; cicloalquilo C3-8, alquiloxi C1-4 y ciano; R3 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, cicloalquilo C3-8 y alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; Het es un anillo heterocíclico de 5 o 6 miembros, seleccionado del grupo que consiste en piridinilo; pirimidinilo; piridazinilo; pirazinilo; pirrolilo; oxazolilo; tiazolilo; imidazolilo; pirazolilo; isotiazolilo; isoxazolilo; oxadiazolilo y triazolilo; R4 se selecciona del grupo que consiste en hidrogeno; alquilo C1-4, alquilo C1-4 sustituido con 1, 2 o 3 átomos de fluoro; (difluorociclopropil)metilo; (ciclopropil)difluorometilo; hidroxialquilo C1-4, cicloalquilo C3-8, cicloalquil C3-8- aIquilo C1-4, alquiloxi C1-4-alquilo C1-6, alquiloxi C1-4, alquiloxi C1-4 sustituido con 1, 2 o 3 átomos de fluoro; cicloalquil C3-8-alquiloxi C1-4, alquiloxi C1-4-alquil C1-4-oxi; alquil C1-4-carbonilo; alquil C1-4-carbonilalquilo C1-4, cicloalquil C3-8-carbonilo; cicloalquil C3-8-carbonilalquilo C1-4, fenilo no sustituido; fenilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo, trifluorometoxi, ciano y alquiloxi C1-4; bencilo no sustituido; bencilo sustituido con 1 o 2 sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-4, trifluorometilo, trifluorometoxi, ciano y alquiloxi C1-4, tetrahidrofuranilo no sustituido; tetrahidrofuranilmetilo; tetrahidropiranilo no sustituido; tetrahidropiranilmetilo; piridinilmetilo; quinolinilmetilo; (NR10R11)alquilo C1-4 y NR10R11; R5 es hidrogeno o fluoro; R10 y R11 se seleccionan independientemente de hidrogeno y alquilo C1-4, o 5 tomados junto con el átomo de nitrogeno anular pueden formar un radical de formula (b-1), (b-2) o (b-3) en donde cada R12, R13 y R14 es independientemente alquilo C1-4 o alquiloxi C1-4; R15 es hidrogeno o alquilo C1-4; cada q1, q2 y q3 se selecciona independientemente de 0, 1, 2, 3 y 4; s1 se selecciona de 1, 2, 3 y 4; cada s2 y s3 se selecciona independientemente de 1 y 2; o una sal o solvato farmacéuticamente aceptable de dicho compuesto.
ARP110100694A 2010-03-09 2011-03-04 Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 AR080754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10155981 2010-03-09

Publications (1)

Publication Number Publication Date
AR080754A1 true AR080754A1 (es) 2012-05-09

Family

ID=42536437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100694A AR080754A1 (es) 2010-03-09 2011-03-04 Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Country Status (22)

Country Link
US (1) US8859543B2 (es)
EP (1) EP2545055B1 (es)
JP (1) JP5746719B2 (es)
KR (1) KR101332585B1 (es)
CN (1) CN102791713B (es)
AR (1) AR080754A1 (es)
AU (1) AU2011226174B2 (es)
BR (1) BR112012022650B1 (es)
CA (1) CA2790571C (es)
CL (1) CL2012002487A1 (es)
CO (1) CO6602133A2 (es)
EA (1) EA022012B1 (es)
ES (1) ES2646827T3 (es)
MX (1) MX2012010391A (es)
MY (1) MY160305A (es)
NZ (1) NZ601931A (es)
PH (1) PH12012501749A1 (es)
SG (1) SG183524A1 (es)
TW (1) TWI504601B (es)
UA (1) UA107952C2 (es)
WO (1) WO2011110545A1 (es)
ZA (1) ZA201206715B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
ES2480341B1 (es) 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
JP6263606B2 (ja) * 2013-05-02 2018-01-17 ファイザー・インク Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
WO2014200885A1 (en) * 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
CA3025594C (en) 2016-06-16 2024-06-18 Janssen Pharmaceutica Nv Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
BR112019020309A2 (pt) 2017-03-29 2020-04-28 Janssen Pharmaceutica Nv derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta
WO2019079469A1 (en) * 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
CR20250050A (es) * 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN110845426A (zh) * 2019-11-29 2020-02-28 都创(上海)医药科技有限公司 一种2-氯-5-氰基嘧啶化合物制备方法
CN114989177B (zh) * 2022-07-11 2023-01-24 江西瑞威尔生物科技有限公司 一种咪唑并吡嗪类化合物的制备工艺

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242513A (en) 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
US4507294A (en) 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
US4376772A (en) 1981-12-09 1983-03-15 Merck & Co., Inc. Use of piperazinyl-imidazo[1,2-a]pyrazines in sedation
DE3666434D1 (de) 1985-05-25 1989-11-23 Yoshitomi Pharmaceutical Oxodiazine compounds
AU6355190A (en) 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
JPH04506215A (ja) 1989-06-13 1992-10-29 スミスクライン・ビーチャム・コーポレイション モノカイン活性干渉
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
KR910011852A (ko) 1989-12-04 1991-08-07 폴 디. 매튜카이티스 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
WO1991019497A1 (en) 1990-06-12 1991-12-26 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
EP0563286A4 (en) 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
WO1998035967A2 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ATE221886T1 (de) 1997-09-02 2002-08-15 Bristol Myers Squibb Pharma Co Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
WO2001058489A1 (en) 2000-02-14 2001-08-16 Japan Tobacco Inc. Preventives/remedies for postoperative stress
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2002034748A1 (fr) 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
EP1343785A2 (de) 2000-12-13 2003-09-17 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
CN1267446C (zh) 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE60204674T2 (de) 2001-03-14 2006-05-18 Eli Lilly And Co., Indianapolis Retinoid x rezeptormodulatoren
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
CA2448317A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating glaucoma v
US20030027820A1 (en) 2001-05-30 2003-02-06 Alteon, Inc. Method for treating fibrotic diseases or other indications V
PL366827A1 (en) 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US7244740B2 (en) 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AU2003207646C1 (en) 2002-01-22 2008-09-18 Vanderbilt University Treating stress response with chemokine receptor CCR5 modulators
KR100974770B1 (ko) 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
US6919340B2 (en) * 2002-04-19 2005-07-19 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
JP2003313126A (ja) 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
CA2484631A1 (en) 2002-05-13 2003-11-27 Merck & Co., Inc. Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
GB0217783D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
DE60309342T2 (de) 2002-08-09 2007-05-16 Eli Lilly And Co., Indianapolis Benzimidazole und benzothiazole als inhibitoren der map-kinase
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7105533B2 (en) 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
TW200413378A (en) 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
AU2003275031B2 (en) 2002-09-23 2006-08-17 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
AU2003271185A1 (en) 2002-10-15 2004-05-04 Takeda Pharmaceutical Company Limited Imidazopyridine derivative, process for producing the same, and use
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1582516B1 (en) 2003-01-10 2013-07-17 Idemitsu Kosan Co., Ltd. Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7329668B2 (en) 2003-02-25 2008-02-12 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US20060100235A1 (en) 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP2292620A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
KR100553752B1 (ko) 2003-10-13 2006-02-20 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
BRPI0415395A (pt) * 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
JP2007509960A (ja) 2003-10-28 2007-04-19 セプラコア インコーポレーテッド イミダゾ［１，２−ａ］ピリジン抗不安薬
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
DE602005013085D1 (de) 2004-06-09 2009-04-16 Oncalis Ag Proteinkinaseinhibitoren
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
AU2005278292B2 (en) 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives
WO2006044509A2 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
AU2005301568B2 (en) 2004-11-08 2011-06-09 Msd K.K. Novel fused imidazole derivative
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006076131A2 (en) 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
KR20070120963A (ko) 2005-03-21 2007-12-26 일라이 릴리 앤드 캄파니 이미다조피리다진 화합물
WO2006100119A1 (en) 2005-03-24 2006-09-28 Glaxo Group Limited Derivatives of imidazo (1,2-a) pyridine useful as medicaments for treating gastrointestinal diseases
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GB0513423D0 (en) 2005-06-30 2005-08-03 Glaxo Group Ltd Novel compounds
JP2009501172A (ja) 2005-07-11 2009-01-15 ノバルティス アクチエンゲゼルシャフト インドリルマレイミド誘導体
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
AR056191A1 (es) 2005-08-23 2007-09-26 Idenix Phatmaceuticals Inc Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
CN101291582A (zh) * 2005-09-02 2008-10-22 艾博特公司 以咪唑为基础的新杂环化合物
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0616571A2 (pt) 2005-09-27 2011-06-21 Hoffmann La Roche oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
EP1945216A1 (en) 2005-11-10 2008-07-23 Schering Corporation Methods for inhibiting protein kinases
BRPI0618520A2 (pt) 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
US20090203732A1 (en) 2006-03-02 2009-08-13 Dashyant Dhanak Thiazolones for Use as P13 Kinase Inhibitors
WO2007145921A1 (en) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
US20080021217A1 (en) 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
JP2009544723A (ja) 2006-07-24 2009-12-17 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤としてのチオゾリジンジオン誘導体
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144743A1 (en) 2006-09-05 2010-06-10 Board Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008063287A2 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
US7563920B2 (en) 2006-10-30 2009-07-21 Draximage Limited Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
MX2009005011A (es) 2006-11-08 2009-05-20 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
AU2007321923A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US7622584B2 (en) 2006-11-24 2009-11-24 Samsung Mobile Display Co., Ltd. Imidazopyridine-based compound and organic light emitting diode including organic layer comprising the imidazopyridine-based compound
JP2010511682A (ja) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ 抗菌性の多環系尿素化合物
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
CA2674530C (en) 2007-01-12 2014-09-16 Banyu Pharmaceutical Co., Ltd. Spirochromanon derivatives
US20080242862A1 (en) 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
JP2010522765A (ja) 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
EP2137184B1 (en) 2007-04-03 2013-05-08 Array Biopharma, Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
EP2155744A1 (en) 2007-04-10 2010-02-24 Lundbeck, H., A/S Heteroaryl amide analogues as p2x7 antagonists
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
MX2009012066A (es) 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
PT2155758E (pt) 2007-05-10 2012-11-12 Biocryst Pharm Inc Compostos de tetrahidrofuro[3,4-d]dioxolano para utilização no tratamento de infecções virais e do cancro
JP5291095B2 (ja) 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー イミダゾピリジンキナーゼ阻害剤
CN101772500A (zh) 2007-06-14 2010-07-07 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
KR101030007B1 (ko) 2007-06-15 2011-04-20 삼성모바일디스플레이주식회사 헤테로방향환 함유 화합물, 이의 제조 방법 및 이를 이용한유기 발광 소자
WO2009002534A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN101790515A (zh) 2007-07-27 2010-07-28 埃科特莱茵药品有限公司 反式-3-氮杂-双环[3.1.0]己烷衍生物
AU2008282885A1 (en) 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
AU2008288390A1 (en) 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
EP2217069A4 (en) 2007-11-09 2012-03-14 Salk Inst For Biological Studi INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
ES2462642T3 (es) 2007-12-14 2014-05-26 F. Hoffmann-La Roche Ag Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
US20110112135A1 (en) 2007-12-21 2011-05-12 Singhaus Jr Robert Ray Imidazo [1,2-A] Pyridine Compounds
EP2224510A1 (en) 2007-12-21 2010-09-01 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
EP2235019A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2009097233A1 (en) 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2009108546A1 (en) 2008-02-26 2009-09-03 Merck & Co., Inc. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
WO2009126691A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2009143156A2 (en) 2008-05-19 2009-11-26 Sepracor Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
EP2297144A1 (en) 2008-05-29 2011-03-23 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
EP2306836B1 (en) 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
JP2011529073A (ja) 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
ATE542813T1 (de) 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
FR2934994B1 (fr) 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5416944B2 (ja) 2008-10-23 2014-02-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5210187B2 (ja) 2009-01-22 2013-06-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8367222B2 (en) 2009-02-27 2013-02-05 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
JP5528427B2 (ja) 2009-03-24 2014-06-25 出光興産株式会社 有機エレクトロルミネッセンス素子
SG175195A1 (en) 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
WO2011021520A1 (ja) 2009-08-19 2011-02-24 出光興産株式会社 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子
KR20120066076A (ko) 2009-11-16 2012-06-21 이데미쓰 고산 가부시키가이샤 방향족 아민 유도체 및 그것을 이용한 유기 전기발광 소자
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10

Also Published As

Publication number Publication date
EP2545055B1 (en) 2017-08-09
PH12012501749A1 (en) 2015-02-25
TW201200519A (en) 2012-01-01
EA201290878A1 (ru) 2013-03-29
ES2646827T3 (es) 2017-12-18
KR101332585B1 (ko) 2013-11-25
AU2011226174B2 (en) 2015-01-22
EP2545055A1 (en) 2013-01-16
KR20120125656A (ko) 2012-11-16
US20120329792A1 (en) 2012-12-27
ZA201206715B (en) 2015-04-29
JP2013521320A (ja) 2013-06-10
CA2790571C (en) 2018-04-24
SG183524A1 (en) 2012-09-27
MX2012010391A (es) 2012-10-10
EA022012B1 (ru) 2015-10-30
NZ601931A (en) 2014-01-31
US8859543B2 (en) 2014-10-14
JP5746719B2 (ja) 2015-07-08
MY160305A (en) 2017-02-28
CA2790571A1 (en) 2011-09-15
UA107952C2 (uk) 2015-03-10
AU2011226174A1 (en) 2012-09-13
HK1176057A1 (zh) 2013-07-19
BR112012022650A2 (pt) 2016-10-25
CN102791713B (zh) 2016-02-03
CL2012002487A1 (es) 2012-11-30
WO2011110545A1 (en) 2011-09-15
BR112012022650A8 (pt) 2017-11-14
CN102791713A (zh) 2012-11-21
CO6602133A2 (es) 2013-01-18
TWI504601B (zh) 2015-10-21
BR112012022650B1 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
AR080754A1 (es) Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
AR078841A1 (es) Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10
ES2824723T3 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR121661A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
ZA202001390B (en) Crystalline forms
AR110026A1 (es) Inhibidores de pde2
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
RU2018140092A (ru) Новые пиразолпиримидиновые производные
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR060537A1 (es) 1,2,4-triazoles trisustituidos
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2015058126A8 (en) Heteroaromatic compounds useful for the treatment of prolferative diseases
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
AR091781A1 (es) Antagonistas del receptor de 5-ht3
HRP20160744T2 (hr) Heterocikličke tvari i njihova uporaba kao modulatora receptora tirozin kinaza tipa iii
AR075383A1 (es) Derivados de triazolo[4,3-b]piridazina
JP2016507551A5 (es)
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
AR073262A1 (es) Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1.
NZ629795A (en) 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal